Advanced phasing techniques in congenital skin diseases
- PMID: 39723554
- PMCID: PMC11883850
- DOI: 10.1111/1346-8138.17597
Advanced phasing techniques in congenital skin diseases
Abstract
Phasing, the process of determining which alleles at different loci on homologous chromosomes belong together on the same chromosome, is crucial in the diagnosis and management of autosomal recessive diseases. Advances in long-read sequencing technologies have significantly enhanced our ability to accurately determine haplotypes. This review discusses the application of low-coverage long-read sequencing, nanopore Cas9-guided long-read sequencing, and adaptive sampling in phasing, highlighting their utility in complex clinical scenarios. Through clinical vignettes, we explore the importance of phasing in gene therapy design for recessive dystrophic epidermolysis bullosa and the role of revertant mosaicism in therapeutic epidermal autografts. Despite its promise, phasing with long-read sequencing faces challenges, including low efficiency in enriching target regions and the inherent error rate of nanopore sequencing. Future developments in long-read sequencing technologies will be critical in overcoming these limitations and expanding the applicability of phasing across various clinical settings.
Keywords: epidermolysis bullosa; long‐read sequencing; nanopore sequencing; revertant mosaicism.
© 2025 The Author(s). The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association.
Conflict of interest statement
Ken Natsuga received grants from J‐TEC (Japan Tissue Engineering Co., Ltd.).
Figures






Similar articles
-
Detection of revertant mosaicism in epidermolysis bullosa through Cas9-targeted long-read sequencing.Hum Mutat. 2022 Apr;43(4):529-536. doi: 10.1002/humu.24331. Epub 2022 Jan 25. Hum Mutat. 2022. PMID: 35077577
-
Cultured Epidermal Autografts from Clinically Revertant Skin as a Potential Wound Treatment for Recessive Dystrophic Epidermolysis Bullosa.J Invest Dermatol. 2019 Oct;139(10):2115-2124.e11. doi: 10.1016/j.jid.2019.03.1155. Epub 2019 May 2. J Invest Dermatol. 2019. PMID: 31054844 Review.
-
Natural gene therapy in dystrophic epidermolysis bullosa.Arch Dermatol. 2012 Feb;148(2):213-6. doi: 10.1001/archdermatol.2011.298. Epub 2011 Oct 17. Arch Dermatol. 2012. PMID: 22004882
-
Revertant mosaic fibroblasts in recessive dystrophic epidermolysis bullosa.Br J Dermatol. 2019 Dec;181(6):1247-1253. doi: 10.1111/bjd.17943. Epub 2019 Jul 8. Br J Dermatol. 2019. PMID: 30924923 Free PMC article.
-
Gene therapy: pursuing restoration of dermal adhesion in recessive dystrophic epidermolysis bullosa.Exp Dermatol. 2014 Jan;23(1):1-6. doi: 10.1111/exd.12246. Exp Dermatol. 2014. PMID: 24107073 Review.
References
-
- Warburton PE, Sebra RP. Long‐read DNA sequencing: recent advances and remaining challenges. Annu Rev Genomics Hum Genet. 2023;25:109–132. - PubMed
-
- Natsuga K, Furuta Y, Takashima S, Nohara T, Kosumi H, Mai Y, et al. Detection of revertant mosaicism in epidermolysis bullosa through Cas9‐targeted long‐read sequencing. Hum Mutat. 2022;43:529–536. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources